Graphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.
UK clears the way for gene-edited crops
Latest NewsPost-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
mRNA – delivering on the promises
OpinionThe past two years could be called the years of messenger RNA (mRNA) technology, with two major biotech companies, BioNTech and Moderna, playing a crucial role in the development of vaccines against COVID-19 and showing the world the way out of the pandemic, along with achieving record sales revenues.
Team identifies factors for COVID-19 vaccine protection
Latest NewsA comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
Graphene
ProductsGraphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.
Advancing cancer immunotherapy
BackgroundSingle cell multiomics has the capacity to address key challenges to developing cell and gene therapies, specifically CAR T-cell therapies. Hear how leading cancer immunotherapy researchers are using these approaches for characterizing the leukapheresis and infusion product, studying the evolution of the cell product in vivo, identifying and defining mechanisms of resistance, and discovering next-generation cell therapies.
AstraZeneca invests in saRNA platform
Latest NewsAstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.
EIF supports translational med with €25m
Latest NewsThe EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
BioSpain 2021, showcasing Spanish biotech leap forward
BackgroundThe largest biotech event organised by a national bioindustry association (AseBio) in Europe and one of the biggest in the world will take place from 27 September to 1 October. To be held in Pamplona-Iruña, the capital of the region of Navarra, and a scientific cluster for biotechnology, BioSpain will feature
a combination of on-site networking opportunities and site visits, an online trade show, presentations,
and panels that will be accessible simultaneously on-site and online.
Managing risks and finding opportunities through logistics
BackgroundBy applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
Europe needs strong incentives for private biotech funding
OpinionThe COVID-19 pandemic has demonstrated how vulnerable human beings and societies are to a new infectious disease, and how important the life science industry is to come up with diagnostic and therapeutic solutions.